References
- Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med.62, 347–360 (2011).
- Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet.38(5), 531–539 (2006).
- Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood108(9), 3204–3209 (2006).
- Chung B, Verdier F, Matak P, Deschemin JC, Maueux P, Vaulont S. Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J.24(6), 2093–2103 (2010).
- Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood108(12), 3730–3735 (2006).
- Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med.13(9), 1096–1101 (2007).
- Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv. Hematol.2010, 358283 (2010).
- Tanno T, Porayette P, Sripichai O et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood114(1), 181–186 (2009).
- Gardenghi S, Ramos P, Marongiu MF et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J. Clin. Invest.120(12), 4466–4477 (2010).
- Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature467(7313), 318–322 (2010).
- Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology139(2), 393–408 (2010).
- De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due to mutations in ferroportin. Haematologica91(1), 92–95 (2006).
- Li H, Rybicki AC, Suzuka SM et al. Transferrin therapy ameliorates disease in β-thalassemic mice. Nat. Med.16(2), 177–182 (2010).
- Moran-Jimenez MJ, Mendez M, Santiago B et al. Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur. J. Clin. Invest.40(6), 511–517 (2010).
- Viatte L, Nicolas G, Lou DQ et al. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood107(7), 2952–2958 (2006).
- Nicolas G, Viatte L, Lou DQ et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat. Genet.34(1), 97–101 (2003).
- Corradini E, Schmidt PJ, Meynard D et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology139(5), 1721–1729 (2010).
- Roy CN. Anemia of inflammation. Hematology Am. Soc. Hematol. Educ. Program.2010, 276–280 (2010).
- Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J. Hepatol.54(1), 173–181 (2011).
- Maes K, Nemeth E, Roodman GD et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood116(18), 3635–3644 (2010).